Company Overview
Company Type: Private Company
Website: www.mantrapharma.ca
Number of Employees: 25
Year Founded: 2006
Total Amount Raised (CAD mm)†: 0.18
Total Rounds of Funding**:2
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Mantra Pharma Inc. operates as a pharmaceutical manufacturing firm that offers generic drugs, vitamins, and supplements under the M brand. It provides various services, such as drug and vaccine administration techniques; accredited medical training; education and training; and warehousing and logistics. It serves owner-pharmacists, salaried employees, and PTAs in Quebec and Canada. The company was founded in 2006 and is based in Brossard, Canada with an additional location in Lévis, Quebec.


Financial Information (Currency: CAD, in mm)
Total Revenue
 75.2
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
 25
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Letarte, Jean-Francois 
President
Paquet, Olivier 
Vice President of Operations
Cadrin, Pierre 
Executive Vice President
Turcotte, Stephane 
Vice President of Marketing


Primary Industry Classification
Pharmaceuticals


Primary Office Location
9150 Leduc Boulevard Suite 201 | Brossard, QC | J4Y 0E3 | Canada
Fax: 450 678 7089


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jun-09-2022
Jun-09-2022
Private Placement
Target
Mantra Pharma Inc.


0.11
Mar-16-2021
Mar-16-2021
Private Placement
Target
Mantra Pharma Inc.


0.03
Jul-17-2020
Sep-01-2020
Spin-Off/Split-Off
Target
Mantra Pharma Inc.

AsiaBaseMetals Inc. (TSXV:ABZ)
-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jul-20-2023
Annual General Meeting
Mantra Pharma Inc., Annual General Meeting, Jul 20, 2023
Jul-20-2023
Shareholder/Analyst Calls
Mantra Pharma Inc. - Shareholder/Analyst Call
Jan-03-2023
Product-Related Announcements
Mantra Pharma inc Introduces the First Generic Alternative to CLAVULIN® (GSK) in Canada
Oct-19-2022
Product-Related Announcements
Mantra Pharma Solidifies Its Position in the Canadian Industry by Launching M-Amoxi-Clav
Sep-22-2022
Product-Related Announcements
Mantra Pharma Launches Several New Products, Planning to Offer No Less Than Six New Molecules by December


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 19, 2023 03:57 AM
Mantra Pharma Inc.
Mantra Pharma
Reports
19
GlobalData

Jun 15, 2023 07:55 AM
Mantra Pharma Inc.
Mantra Pharma
Reports
19
GlobalData

Mar 15, 2023 03:08 AM
Mantra Pharma Inc.
Mantra Pharma
Reports
18
GlobalData

Dec 13, 2022 12:20 AM
Mantra Pharma Inc.
Mantra Pharma
Reports
18
GlobalData

Sep 21, 2022 07:49 AM
Mantra Pharma Inc.
Mantra Pharma
Reports
18
GlobalData

Jun 14, 2022 02:59 AM
Mantra Pharma Inc.
Mantra Pharma
Reports
18
GlobalData

Mar 14, 2022 07:52 AM
Mantra Pharma Inc.
Mantra Pharma
Reports
18
GlobalData

Dec 17, 2021 01:08 AM
Mantra Pharma Inc.
Mantra Pharma
Reports
18
GlobalData

Sep 17, 2021 10:53 AM
Mantra Pharma Inc.
Mantra Pharma
Reports
15
GlobalData

Jun 15, 2021 12:45 AM
Mantra Pharma Inc.
Mantra Pharma
Reports
15


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Chowdhry CA, CPA, Rajinder I.

23,405,617

-

-

Jun-09-2022



No Data Available.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Aug-11-2023
Jun-30-2023
Mantra Pharma Inc.
SEDAR
Interim Financial Statements
242 KB
Jun-15-2023
-
Mantra Pharma Inc.
SEDAR
Management Proxy Materials
69 KB
Jun-15-2023
-
Mantra Pharma Inc.
SEDAR
Management Proxy Materials
320 KB
Jun-15-2023
-
Mantra Pharma Inc.
SEDAR
Management Proxy Materials
52 KB
Jun-15-2023
-
Mantra Pharma Inc.
SEDAR
Management Proxy Materials
68 KB
Jun-15-2023
-
Mantra Pharma Inc.
SEDAR
Management Proxy Materials
254 KB
May-12-2023
-
Mantra Pharma Inc.
SEDAR
Notice of the Meeting and Record Date
313 KB
May-11-2023
Mar-31-2023
Mantra Pharma Inc.
SEDAR
Interim Financial Statements
229 KB
Feb-23-2023
Dec-31-2022
Mantra Pharma Inc.
SEDAR
Interim Financial Statements
224 KB
Feb-17-2023
Sep-30-2022
Mantra Pharma Inc.
SEDAR
Statement of Executive Compensation
207 KB

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Letarte, Jean-Francois 
President
-
450 678 7089

Paquet, Olivier 
Vice President of Operations
-
450 678 7089

Cadrin, Pierre 
Executive Vice President
-
450 678 7089

Turcotte, Stephane 
Vice President of Marketing
-
450 678 7089

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
